Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment

Stopped early · Not applicable

Conditions studied: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8

In brief

This is a non-significant risk, double-blinded, randomized, registrational study to compare the effectiveness of two digital, software only, medical devices (SaMD) (attune™ and cerena™) in reducing cancer-related anxiety and depression symptoms when used adjunctively with multidisciplinary (medical, psychosocial) oncology usual care regimens for up to 10 weeks. Study population will consist of up to 553 participants with stage I-III breast cancer or stage I-III NSCLC. The primary endpoint is percent improvement in anxiety symptoms at Week 10 and secondary endpoints of percent improvement in depressive symptoms will be assessed at Week 12. An interim analysis for efficacy and futility will be conducted once 236 participants have completed the study.

Key facts

Study ID

NCT04862195

Run by

Blue Note Therapeutics

People needed

31

Starts

2021-05-15

Expected to finish

2022-09-01

Last updated by the study team

2022-09-13

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage I-III breast cancer or Stage I-III NSCLC who are currently in active treatment or have completed initial cancer directed treatments (surgery, radiation, chemotherapy) within the past 3 months;
• Are experiencing at least moderate anxiety (GAD-7 >10) or mild-to-moderate depression (PHQ-8 score 5-11);
• Are fluent in English; and
• Have access to smartphone, or tablet capable of running iOS or Android software.

You may not qualify if…

• Previous history of cancer;
• <2-yr survival prognosis as determined by treating clinician;
• Currently participating in investigative CBT trial for treatment of anxiety or depression;
• Participant is unable to complete training, has cognitive deficits, more severe psychiatric conditions, lack of access to internet accessible device or psycho-social conditions (e.g., other social conditions, that would interfere with adherence to self-directed care), such that in investigator's opinion the participant would be unable to complete the study;
• Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other Blue Note Therapeutics-sponsored study; and
• PHQ-9 Q9 response >0 AND Columbia Suicide Severity Risk Scale (or equivalent) score of Category 2- "suicidal ideation" at screening.

Where it is running

• OPN Healthcare — Glendale, California, United States
• Oncology Physicians Network Healthcare — Los Alamitos, California, United States
• Redlands Oncology — Redlands, California, United States
• Eastern CT Hematology and Oncology Associates — Norwich, Connecticut, United States
• Illinios Cancer Care — Peoria, Illinois, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Rogel Cancer Center | University of Michigan — Ann Arbor, Michigan, United States
• SCL Health — Billings, Montana, United States
• New Jersey Center for Cancer Research — Brick, New Jersey, United States
• New York Cancer & Blood Specialists — Port Jefferson Station, New York, United States
• Tri-County Hematology and Oncology-Massillon — Massillon, Ohio, United States
• MD Anderson — Houston, Texas, United States
• Northwest Medical Specialty — Tacoma, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.